enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. A New Alzheimer’s Drug May Be the Most Effective One Yet - AOL

    www.aol.com/alzheimer-drug-may-most-effective...

    Lilly Biotechnology Center in San Diego, Calif. Credit - Getty Images. O n July 2, the U.S. Food and Drug Administration (FDA) approved a new drug for treating Alzheimer’s disease. Donanemab, or ...

  3. FDA approves Alzheimer’s treatment that has been shown to ...

    www.aol.com/news/fda-approves-alzheimer...

    The agency’s approval was based on a late-stage clinical trial of 1,700 people that showed the drug slowed the progression of Alzheimer’s by about 35% after 18 months, compared to a placebo ...

  4. Eli Lilly Alzheimer's drug approved by US FDA - AOL

    www.aol.com/news/us-fda-approves-lillys...

    The approval for donanemab, to be sold under the brand name Kisunla, followed the recommendations of the agency's outside experts, who unanimously backed its use in patients with early Alzheimer's ...

  5. Donanemab - Wikipedia

    en.wikipedia.org/wiki/Donanemab

    Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.

  6. FDA approves donanemab, Eli Lilly’s treatment for early ...

    www.aol.com/fda-approves-donanemab-eli-lilly...

    In trials of Leqembi, the drug that’s already on the market, some participants also had ARIA, but it was at a lower rate than seen in the donanemab trial. Leqembi has also been tied to patient ...

  7. US FDA delays Lilly Alzheimer's drug decision, calls for ...

    www.aol.com/news/us-fda-delays-lilly-alzheimers...

    The FDA's decision came as a surprise to company officials and many Alzheimer's experts, who had expected a full approval for Lilly's drug donanemab this month based on clinical trial data last ...

  8. In an unusual move, FDA postpones approval decision for Lilly ...

    www.aol.com/news/unusual-move-fda-postpones...

    Lilly applied to the FDA for approval of the drug in July, after late-stage clinical trial data showed it slowed the progression of Alzheimer’s by 29% after 18 months, compared to a placebo.

  9. US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10

    www.aol.com/news/us-fda-panel-discuss-eli...

    Lilly's donanemab was declined accelerated approval by the FDA in January 2023, and on March 8, the agency said it would hold a meeting of its advisers to discuss the drug, further delaying its ...